Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials.
Ontology highlight
ABSTRACT: The need to test anticancer drugs in multiple indications has been addressed by basket trials, which are Phase I or II clinical trials involving multiple tumor subtypes and a single master protocol. Basket trials typically involve few patients per type, making it challenging to rigorously compare responses across types. We describe the use of permutation testing to test for differences among subgroups using empirical null distributions and the Benjamini-Hochberg procedure to control for false discovery. We apply the approach retrospectively to tumor-volume changes and progression-free survival in published basket trials for neratinib, larotrectinib, pembrolizumab, and imatinib and uncover examples of therapeutic benefit missed by conventional binomial testing. For example, we identify an o
SUBMITTER: Palmer AC
PROVIDER: S-EPMC8022348 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA